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Abstract
Atherosclerosis, the largest killer in the western world, arises from build-up 
of plaques at the artery walls and can result in cardiovascular disease. Low- and 
high-density lipoproteins are involved in the disease development by depositing 
and removing lipids to and from macrophages at the artery wall. These processes 
are complex and not fully understood. Thus, determining the specific roles of the 
different lipoprotein fractions involved is of fundamental importance for the treat-
ment of the disease. In this chapter, we present the state of the art in lipoprotein 
structure with focus on the comparison between normolipidemic and hypertri-
glyceridemic individuals. Then we discuss lipid transfer between lipoproteins and 
receptor-free cellular membranes. Although these models lack any receptor, key 
clinical observations are mirrored by these, including increased ability of HDL to 
remove lipids, in contrast to the ability of LDL to deposit them. Also effects of satu-
rated and unsaturated lipids in the presence and absence of cholesterol are revised. 
These models can then be used to understand the difference in functionality of 
lipoproteins from individuals showing different lipid profiles and have the potential 
to be used also for the development of new HDL therapies.
Keywords: lipoprotein structure, SAXS, lipid exchange, lipid transfer,  
neutron scattering
1. Introduction
This chapter starts by discussing the main compositional and structural proper-
ties of lipoproteins, which are water-soluble, heterogeneous nanoparticles respon-
sible for carrying lipids, cholesterol and triglycerides in the body. The differences in 
their composition and structure are strictly related to how the different lipoproteins 
are produced and what their roles are in the body. We then move on to discuss the 
relationship between how lipoprotein type and lipoprotein subclass relate with the 
risk to develop atherosclerosis. We review recent evidence that suggests differences 
in low-density lipoprotein (LDL) overall size, shape and protein layer thicknesses 
within small dense LDL subfractions of normolipidemic and hyper triglyceridemic 
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individuals. This is of importance since structural differences across a certain 
lipoprotein class or subclass are not taken into account in clinical studies and this 
might explain controversies in the role of, for example, small dense LDL in the 
development of atherosclerosis. We then move on to discuss how lipoprotein capac-
ity for lipid transfer and lipid exchange has been studied along the years and focus 
on recent results that quantify these abilities using simplistic model membranes 
lacking specific receptors. Despite the simplicity of these model systems, the results 
mirror those obtained for cholesterol efflux and in clinicals studies. Finally, we dis-
cuss advances in plaque remodelling therapies based on the engineering of nanopar-
ticles mimicking nascent high-density lipoprotein (HDL) particles with focus on the 
challenges for the formulation of therapies that are effective in the clinics.
2. Lipoproteins are nanoparticles, made of lipids and apolipoproteins
2.1 Lipoprotein metabolism
Lipoproteins are the carriers of fat in the body. Plasma lipoproteins are secreted 
mostly by the liver and the intestine, whereas lipoproteins carrying lipids in the 
central nervous system are secreted mainly by the glial cells [1]. In Figure 1, the two 
ways by which plasma lipoproteins are formed are summarised. Chylomicrons, the 
largest and the least dense lipoprotein type, are produced in the intestine after a 
meal. Their size varies and depends on the amount of fat consumed during a meal. 
For instance, during fasting, chylomicrons are small and contain low amounts of 
triglycerides whereas a high-fat meal will result in the formation of larger particles, 
Figure 1. 
(A) Lipoprotein metabolism: Lipid-free ApoA1 is produced by both the intestine and the liver. It gains 
phospholipids and cholesterol via the ATP binding cassette A1 (ABCA1) to form lipid-poor ApoA1; it gains 
further lipids from peripheral tissues to form nascent discoidal HDL, which obtains free cholesterol (FC) from 
macrophages via interaction with ABCA1 and ABCG1 transporters. The FC is esterified by lecithin-cholesterol 
acyltransferase (LCAT) to form mature spherical HDL. Mature HDL can interact with the scavenger receptor 
class B type-1 (SR-B1) in the liver resulting in the exchange of unesterified cholesterol in both directions. 
Cholesteryl esters (CE) are transferred to VLDL via the cholesteryl ester transfer protein (CETP) for eventual 
uptake by the LDLR in the liver. The progression from VLDL to LDL occurs via hydrolysis by lipoprotein 
lipases (LPL). Phospholipids and triglycerides (TG) are transferred to HDL from VLDL via the phospholipid 
transfer protein (PLTP) resulting in HDL remodelling. Hepatic and endothelial lipases (HL/EL) also promote 
HDL remodelling. Insert: B. lipoprotein structure with a core of cholesterol esters and triglycerides.
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rich in triglycerides [2]. They undergo hydrolysis of triglycerides resulting in 
chylomicron remnants which are cleared via the liver [3]. Then, very low-density 
lipoproteins (VLDL) are produced in the liver. VLDL are the next least dense 
lipoprotein type, rich in triglycerides and their size depends on the production of 
triglycerides in the liver: the higher the production, the larger the secreted VLDL. 
These particles are hydrolysed in muscle and adipose tissues by lipoprotein lipases 
(LPL) resulting in the removal of the triglycerides and the formation of intermedi-
ate density lipoprotein (IDL), which are lipoprotein particles rich in cholesterol 
[2]. Further hydrolysis via LPL occurs and results in the formation of LDL, which 
is even richer in cholesterol and accounts for the principal carrier of cholesterol in 
circulation.
HDL formation and metabolism, on the other hand, starts with the production 
of apolipoprotein A1 (ApoA1) in the intestine and liver [4]. ApoA1 initial lipida-
tion starts with the addition of both phospholipids and cholesterol from peripheral 
tissues via its interaction with the ATP-binding cassette A1 (ABCA1) transporter. 
Further lipid uptake mediated by ABCA1 and ABCG1 transporters leads to the 
formation of the “nascent”, discoidal HDL. Free cholesterol is then esterified by 
lecithin-cholesterol acyltransferase (LCAT), resulting in the formation of mature, 
spherical HDL with a core full of cholesterol esters [4]. Both nascent and mature 
HDL can interact with the scavenger receptor class B type-1 (SR-B1) in the liver 
and undergo transfer of cholesterol esters towards SR-B1 and exchange of unesteri-
fied cholesterol in both directions [5]. The transfer of cholesterol esters also occurs 
via the cholesteryl ester transfer protein (CETP) to VLDL and LDL for eventual 
uptake by the LDL receptor (LDLR) in the liver [6]. The transfer of phospholipids 
and triglycerides from VLDL to HDL is facilitated by phospholipid transfer protein 
(PLTP), resulting in HDL remodelling. The hydrolysis of HDL phospholipids and 
triglycerides via hepatic and endothelial lipases (HL and EL) also results in HDL 
remodelling [7].
2.2 Lipoprotein composition
Lipoproteins are very heterogeneous in composition and differ in terms of 
their proportions of constituent proteins, cholesterol/cholesteryl esters, triglyc-
erides and phospholipids (Table 1). The proteins responsible for the stability of 
the lipoprotein structure and their function in lipid transport and metabolism are 
known as apolipoproteins. Apolipoproteins vary in their size and overall struc-
ture, but they share a structure rich in amphipathic alpha helices, which are prone 
to interact with lipids and fats in aqueous environments such as plasma. In gen-
eral, the larger the particle the higher the content ratio between lipids to proteins, 
which makes them less dense. Lipoproteins differ also in the main apolipoprotein 
they present. Apolipoprotein B100 (ApoB100) [9] is present only in VLDL, IDL 
VLDL LDL HDL
Diameter/ nm 30–80 18–25 5–12
Cholesterol/% (w/w) ~6 ~7 ~4
Phospholipids/% (w/w) ~17 ~21 ~29
Triglycerides/% (w/w) ~55 ~6 ~4
Protein/% (w/w) ~8 ~20 ~50
Table 1. 
Biochemical composition and size of major lipoprotein types [8].
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and LDL, since they are all formed from chylomicrons. ApoB100 is one of the 
largest proteins known (~4500 residues) and therefore is irreversibly bound 
to these particles. The rest of the apolipoproteins are reversible and exchange 
between the different lipoprotein types. For example, Apolipoprotein C (ApoC) 
and Apolipoprotein E (ApoE) are commonly found in VLDL and LDL [10]. 
The main protein present in HDL is ApoA1, contributing to about 70% of total 
protein content in all HDL [10]. The second most abundant is Apolipoprotein 
A2 (ApoA2) [10] followed by a combination of various other proteins including 
ApoC, E and Apolipoprotein J. While almost all HDL contain ApoA1 [11], the 
remaining apolipoproteins vary across different HDL types and subclasses [10].
2.3 Lipoprotein classification
As discussed previously, lipoprotein types vary drastically in their biochemical 
composition, which determines their size and density (Table 1). To further increase 
the degree of complexity, there are more subdivisions to these main categories. For 
example, using ultra-centrifugation, LDL can be subdivided in six subfractions 
which range from the large buoyant LDL (lbLDL) subfractions to the small dense 
LDL (sdLDL) subfractions [12, 13]. As their names suggest, these subfractions differ 
in size and density. For HDL, there are generally five distinct subpopulations with 
slight variations in composition, but most notably differences in size and density. 
HDL was first described by differences in density according to ultra-centrifugation 
techniques categorising HDL into two distinct groups [14]: i) HDL2, which is lower 
in density due to a higher lipid content (1.063–1.125 g mL−1), and ii) HDL3, which 
is slightly higher in density owing to its higher protein content (1.125–1.21 g mL−1). 
These groups can be further categorised by their size, using polyacrylamide gradient 
gel electrophoresis (GGE) resulting in five additional subclasses ranging in size from 
7.2–12.0 nm in diameter [15]. By means of GGE, HDL particles can also be classi-
fied based on their surface charge into particles that migrate to either pre- β - or 
α-positions. Pre- β-position corresponds to lipid-free ApoA1, lipid-poor ApoA1, and 
most discoidal HDLs, whereas spherical, mature HDL migrate to α -position [16].
2.4 Lipoprotein structure
The structure of lipoproteins was studied already in the late 1970s by small angle 
X-ray scattering (SAXS) [13, 17–19] and in the early 1980s by small angle neutron 
scattering (SANS) [20]. It was then proposed their core-shell structure today widely 
accepted: lipoproteins are nanoparticles that consist of a core of cholesterol esters 
and triglycerides, with an outer monolayer of lipids and cholesterol, all encased 
by apolipoproteins. For the cholesterol richer LDL, a gel-liquid phase transition 
occurs below body temperature, Tm. In the early SAXS-based structure, the core 
was thought to organise in cholesteryl rich concentric layers maintaining a spherical 
structure [13] below Tm. More recently, cryogenic transmission electron micros-
copy (cryo-EM) was used to demonstrate that LDL particles are ellipsoidal having 
a stack of parallel cholesteryl ester layers below Tm [21–23]. The SAXS model for 
LDL was then revised in 2017 to account for LDL super-ellipsoid shape and planar 
lamellar ordered cholesteryl ester layer packing in the core below Tm (Figure 2A), 
and spherical LDL with the melted core above Tm [25] (Figure 2B). In contrast to 
cryo-EM, SAXS allows the probing of a large number of LDL particles in a relatively 
short time and in a physiological-like environment. Therefore, larger and systematic 
studies can be done providing a range of structural detail that is unprecedented: not 
only the size but also the shape of the overall particle can be determined, as well as 
the inner structure of the core and the outer protein shell.
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3. Lipoproteins and atherosclerosis
Atherosclerosis is a chronic inflammatory disease considered to be the larg-
est killer in western countries [26]. It is characterised by the plaque build-up in 
artery walls and can lead to cardiovascular diseases (CVD), giving rise to ischemic 
heart disease and strokes [27]. It is accepted that structural and compositional 
differences between HDL and LDL play a large role in their contributions to 
atherosclerosis [28]. The plaque build-up originates from LDL deposition into the 
artery walls [29], which are then oxidised and cause the upregulation of adhesion 
molecules on the surface of the endothelium of the arteries and the recruitment 
of monocytes to the forming lesion [30]. These then differentiate in macrophages 
which express scavenger receptors on their surface that mediate the uptake of 
even more LDL. This leads to the transformation of macrophages into foam cells, 
and the formation in the arteries of plaques that consist of apoptotic and necrotic 
macrophages, cholesterol crystals and other extracellular components [31]. Upon 
the rupture of these plaques, thrombus material enters the blood stream and can 
lead to heart attacks or other CVD related phenomena. As opposite to the role 
of LDL in atherosclerosis development, HDL have been instead shown to play a 
preventative role by a process known as reverse cholesterol transport (RCT) [32]. 
By this process, cholesterol is removed from the lipid-filled foam cells at the artery 
wall and deposited in the liver where it is cleared from the body [33–35]. The 
cholesterol removal occurs via efflux by various means, including passive aqueous 
diffusion or active, receptor/transporter mediated transfer [36]. Additionally, the 
presence of HDL has been shown to prevent the oxidation of the LDL and there-
fore helps prevent the development to atherosclerosis [37]. While both lipoprotein 
types are characterised by a lipid binding activity, their abilities to exchange lipids 
and to transport cholesterol differ drastically. Indeed, LDL mainly deposit lipids 
and cholesterol to artery walls, whereas the main role of HDL in the blood is to 
catalyse cholesterol efflux thereby removing excess cholesterol from macrophages 
Figure 2. 
The updated LDL model based on SAXS data below (A) and above Tm (B) describes a superellipsoid of 
revolution or a sphere with core-shell structure, respectively. LDL phenotype A described a LDL sample 
enriched with lbLDL while phenotype B describes a LDL fraction enriched with sdLDL. Phenotype B is 
linked to a higher risk to develop atherosclerosis (C) Some structural parameters for total LDL fractions as 
well as LDL subfractions lbLDL and sdLDl for subject A presenting normal lipid serum values and subject B 
presenting high triglyceride serum values (D) Data in D is taken from Jakubauskas et al 2020 [24].
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trapped at artery walls [28]. Therefore, HDL and LDL are commonly known as 
‘good’ and ‘bad’ cholesterol respectively.
There are several controversies regarding the role of HDL and LDL in the devel-
opment of atherosclerosis. On one hand, increased levels of HDL are correlated to 
reduced atherosclerotic risk due to increased RCT efficiency [35] and, in some other 
cases, shown to have a neutral [38] or even negative correlation [39] to the preven-
tion of atherosclerotic development. On the other hand, high LDL levels are related 
to high risk for development of atherosclerosis even though the total cholesterol 
LDL concentration often fails as a CVD biomarker [40]. This could be due to the 
pro-atherogenic effect of LDL [41] being counteracted by the anti-atherogenic 
effect of HDL [42]. Indeed, the ratio between LDL and HDL has been suggested as a 
better biomarker than their individual serum levels [40].
3.1 Different atherogenic capacity of lipoprotein subclasses
The LDL subclass distribution varies significantly within the population with two 
main LDL phenotypes [43]: the healthy one (phenotype A), enriched with lbLDL 
subfractions, and the unhealthy one (phenotype B), enriched with sdLDL subfrac-
tions [44] (Figure 2C). LDL size is an alleged marker for CVD risk since there is a 
positive correlation between LDL size and HDL concentration, and a negative cor-
relation between LDL size and triglyceride concentration [43]. However, it is unclear 
whether it is the LDL concentration or their particle size which is the key parameter 
to predict CVD risk. Interestingly, there is some genetic, age and sex related predis-
position for sdLDL. For example, a low-fat diet can contribute to a phenotype B in 
individuals with a genetic predisposition for sdLDL [45].
Recently, sdLDL fractions of normal and hyper triglyceridemic subjects were 
shown to have similar biochemical composition but different sizes and protein rich 
shell layer thicknesses [24] (Figure 2D). This suggests that LDL size and structure 
are not directly a consequence of composition and diet, mirroring the data found 
for individuals with a predisposition for sdLDL [45]. In particular, the protein rich 
shell layer thickness seems a very important parameter to consider since the protein 
conformation within this layer is determinant for further interaction with receptors 
and other biomolecules in the body. These structural analyses raise the following 
questions: are sdLDL subclasses from healthy and hyper triglyceridemic subjects 
equally pro-atherogenic? If not, is this due to the differences in the presence of spe-
cific apolipoproteins or post translational modifications in the protein-rich shell?
Finally, measuring total plasma cholesterol concentrations in clinics is per se 
insufficient to reliably determine the LDL atherogenic potential in a particular 
individual, as the LDL size-distribution component is not accounted for. The 
detailed understanding of LDL ultrastructure seems necessary to evaluate the 
atherogenicity of the individual LDL subfractions with the ultimate aim to develop 
effective diagnostic and therapeutic tools against CVD. Indeed, the SAXS analysis 
of the total LDL fraction and its subfractions shows that SAXS has the potential to 
discern between LDL phenotypes directly from the total LDL measurement [24] 
(Figure 2D), which could be used to extract information on the sdLDL structural 
parameters between subjects with a range of clinical conditions.
The role of the different HDL subclasses in the development of atherosclerosis 
is less studied and the results are controversial. A 2015 study found no evidence for 
any changes in HDL subclasses profiling for individuals with nonalcoholic fatty 
liver disease (NAFLD) [46], a disease associated with increased cardiometabolic 
risk. Another study found that HDL2b subclass was enriched in Hispanic women 
with LDL phenotype B [47]. Preliminary results from our group suggest that 
HDL main fractions and subfractions size differs between normolipidemic and 
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hypertriglyceridemic individuals. These contrasting results indicate that more 
research is needed to understand the differences in HDL subclasses across various 
lipid metabolism disorders. Differences in HDL and LDL subclass structure rather 
than their relative proportion might be relevant for their function and their role in 
the development of atherosclerosis. Structural studies in combination with detailed 
compositional analysis by means of lipidomics and proteomics, as well as post-
translational modifications, are needed to advance the field.
4. Determining lipid exchange capacity by lipoproteins
As already discussed, LDL function is counteracted by HDL function, and lipid 
exchange is a key process for their functions. Lipid exchange is known to be inde-
pendent of protein exchange [48–51]. Lipid exchange (where no net transfer takes 
place) and lipid transfer between lipoproteins of different types (i.e. between HDL 
and LDL) are known to occur, both in vitro and in vivo, for phospholipids, cho-
lesterol, and sphingomyelin [52–54]. It also occurs between lipoproteins and lipid 
microemulsions [20, 55], lipid vesicles [56, 57], and cells [58]. The older studies 
used chemical analysis and focused on net changes in lipoprotein particle composi-
tion upon a given equilibration time. Therefore, these studies did not monitor the 
exchange processes directly. Only the work by Maric et al. [57] measured the kinet-
ics of lipid exchange directly between lipoproteins and lipid vesicles making use of 
deuterated lipids and SANS.
It is well accepted that there are several pathways for lipid transfer and choles-
terol uptake. The main pathway is through receptor-mediated endocytosis, in which 
lipoprotein binding to LDL receptors takes place for ApoB100 and ApoE containing 
lipoproteins [59, 60]. Another mechanism involves scavenger receptor class B family 
(SR-B) receptors [61], that mediate the selective core lipid transfer from lipoprotein 
particles to cells and tissues. Lipid exchange and lipid transfer can potentially occur 
via lipoprotein endocytosis and subsequent transcytosis in endothelial cells [62, 63]. 
Finally, direct lipid exchange or lipid transfer from lipoprotein particles to the cell 
membrane also occurs, as discussed above. Recently, spontaneous lipid transfer to 
receptor free model membranes was demonstrated by cryo-EM, fluorescence cross 
correlation spectroscopy and spectral imaging, regardless of lipoprotein type [64]. 
In particular, lipid transfer affected the model membrane properties, with HDL 
having the most dramatic effect in lipid packing and collective lipid diffusion.
4.1 Quantification of lipid exchange by lipoproteins
Quantification of lipid exchange and transfer is challenging, and examples were 
scarce in literature until recently. Browning et al. [65] presented a new protocol to 
follow interactions of human lipoproteins with model membranes using neutron 
reflection. HDL and LDL from healthy male adults were incubated with model 
phospholipid membranes in physiological-like conditions. The study showed that 
HDL was able to remove more lipids from the model membranes than LDL, whilst 
LDL deposited more lipids than HDL. The lipid exchange studies on simplified 
model systems mirrored the function of lipoproteins in the body!
Following reports using the same protocol showed that the inclusion of charged 
lipids in the model membranes led to unaffected quantity of lipids deposited but 
increased lipid removal by HDL [66]. The lipid exchange did not seem to affect 
the lipoprotein structure, as determined by SANS [57]. Then, the ability of the 
level of lipid unsaturation and of the presence of cholesterol to affect the lipid 
exchange capacity of lipoproteins was investigated [67]. The presence of acyl chain 
Management of Dyslipidemia
8
unsaturation dramatically decreased the quantities of lipids deposited and removed 
by the lipoproteins, regardless of the lipoprotein type (Figure 3). In other words, 
HDL and LDL have a greater affinity for saturated rather than unsaturated lipids, 
though LDL to a lesser extent. The difference in ease of lipid removal between 
the lipoprotein types could be explained by variance in the specific protein-lipid 
interactions. Different conformations of ApoA1 (the main protein in HDL) were 
shown to have varying binding affinities to unsaturated lipid vesicles [68]. The 
increased ease for saturated lipid removal is likely due to the increased mobility of 
said lipids within the fluid model membrane: saturated phospholipids were shown 
to have greater mobility than their unsaturated counterparts in both gel and fluid 
phases [69].
The presence of cholesterol also had a large impact on the amounts of lipids 
exchanged and removed [67] (Figure 3). In the bilayers comprising saturated 
lipids, the presence of cholesterol decreased the amounts of lipids exchanged and 
removed through HDL whereas, in the case of the unsaturated lipids, the presence 
of cholesterol made little difference when interacting with HDL. LDL, on the other 
hand, did not follow the same pattern. Indeed, including 10 mol% cholesterol in the 
saturated bilayer increased the amount of lipids exchanged. Upon further increas-
ing to 20 mol%, a similar value was found to that of the saturated bilayer alone. For 
the unsaturated model membranes, the presence of 20 mol% cholesterol also gave 
similar values to that of the bilayer alone. However, in terms of removal, for both 
the saturated and unsaturated bilayers, the presence of cholesterol increasingly 
reduced the quantity of lipids removed. It is possible that the presence of cholesterol 
may inhibit the mobility of phospholipids [70] and cause it to localise preferentially 
towards saturated lipids [71]. However, there were no clear systematic changes 
Figure 3. 
Relative lipid exchange and removal for HDL or LDL particles interacting with membranes formed with 
saturated (dDMPC) and unsaturated (dPC) phospholipids with and without cholesterol. Results are shown for 
HDL (A, B) and LDL (C, D) regarding exchange (A, C) and removal (B, D). Replotted with permission from 
Waldie et al 2020 [67].
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when cholesterol was incorporated into the bilayer, thus it is difficult to pinpoint 
the exact cause of the changes seen. LDL has also been shown to preferentially bind 
to rafts of saturated lipid with cholesterol [72]. Since no reduction or increase in 
exchange was seen due to cholesterol, it is likely that the specific lipoprotein-lipid 
interactions determine the final quantities of lipids exchanged and removed.
To further look into this, LDL with differing compositions were used against the 
model membranes. It was found that with increasing density of LDL, i.e. increasing 
percentage of protein, greater levels of exchange were observed [67]. These findings 
can be explained by the difference in ApoB100 (the main protein in LDL) found 
on smaller, more dense LDL particles. Denser LDL particles contain regions with 
altered epitopes [73] that may house part of the lipid-binding region of LDL [74] 
and thus affect their binding and interactive activities.
Access to the neutron beam is limited and highly specialised personnel are 
needed for these experiments. Methodology based on attenuated total reflection 
Fourier transfer infrared spectroscopy (ATR-FTIR) seems an accessible comple-
mentary alternative method to determine lipid exchange [75], which is far more 
accessible and exists in many laboratories as a benchtop technique.
5. Plaque remodelling by HDL therapy
As already discussed in Section 2, and as shown by Framingham Heart Study 
[76, 77] and later on by the Atherosclerosis Risk in Communities study [78], there is 
strong inverse association between HDL-cholesterol levels and CVD risk. Changes 
in lifestyle, such as weight loss, increase of physical activity, reduction in saturated 
fat intake, and low alcohol intake can alone increase HDL-cholesterol levels by up 
to 20%. However, lifestyle changes alone are not sufficient to prevent and reduce 
mortality in atherosclerosis. Thus, over the years there have been many pharma-
cological interventions aimed at raising circulatory HDL-cholesterol levels while 
decreasing LDL-cholesterol levels [79–81]. Nevertheless, these interventions have 
not resulted in the expected reduction in CVD events, suggesting that HDL func-
tionality, rather than changes in HDL levels per se might have a role in the disease 
progression. For this reason, the focus on anti-atherosclerotic solutions shifted 
to therapies that use the ability of HDL and its main apolipoprotein (ApoA1) to 
remove cholesterol from macrophages and that have thus the potential to reduce the 
plaques size and the steric burden at the arterial wall. One of these approaches led 
to the use of ApoA1 Milano, a natural variant of ApoA1 endowed with higher ability 
to stimulate cholesterol efflux and better anti-inflammatory and plaque-stabilising 
properties with respect to the wild-type protein [82]. Infusions of the Milano vari-
ant in complex with phospholipids (ETC-216) were used in patients with high CVD 
risk and resulted in the reduction of the atheroma volume in one study [83] but a 
new formulation (MDCO-216) did not result in plaque regression in patients with 
acute coronary syndromes and on statin treatment. Treatments based on wild-type 
ApoA1 have also been explored. CER-001 is a formulation of human recombinant 
ApoA1, sphingomyelin and phospholipid. It regressed atherosclerosis and increased 
RCT in mice [84] but failed to regress plaques in patients on statins with acute 
coronary syndrome and high plaque burden [85]. Short-term infusions of another 
formulation of HDL with wild-type ApoA1 and phospholipids (CSL111) showed 
improvement in the plaque characterisation index and quantitative coronary score, 
but the positive effects were accompanied by hepatotoxicity, thus the clinical 
development halted [86]. Later on, a new formulation (CSL-112) was developed, 
and its administration has been found to increase the RCT with no adverse effects in 
humans so far [87]. A phase III clinical study is currently ongoing and is expected 
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to conclude in 2022 (NCT03473223), assessing the potential benefits of CSL112 in 
reducing adverse cardiovascular events in subjects with acute coronary syndrome.
ApoA1 mimetic peptides have also been explored in the treatment of the adverse 
effects of atherosclerosis. These have the advantage to be structurally simpler than 
the native full-length protein, although retaining the same biological functions, and 
have the potential to be administered orally instead of via injection. One of these 
ApoA1 mimetic peptides is Rev-D4F, which reduced atherosclerotic lesion area and 
macrophage content at the lesion site in Apoe−/− mice, while also decreasing LDL 
oxidation [88]. Another ApoA1 mimetic, RG54, showed increased glucose toler-
ance, was able to stimulate cholesterol efflux from macrophages, and prevented the 
formation of atherosclerotic plaques in Apoe−/− mice [89]. Finally, 2F*, a photo-
activatable ApoA1 mimetic peptide, was able to increase cholesterol efflux in stably 
transfected baby hamster kidney cells [90]. Although very promising, these pep-
tides have been explored only from a pre-clinical point of view and their efficacy in 
humans and lack of side effects have still to be proved.
Another apolipoprotein that has been suggested as a good candidate for HDL 
therapy is ApoE. ApoE is well known for its atheroprotective properties including 
the ability to induce RCT from peripheral cells to the liver [91] and to stimulate cho-
lesterol efflux from macrophages thus, in turn, preventing the formation of foam 
cells in the development to atherosclerosis [92, 93]. Various studies have shown 
ApoE to have an increased ability to protect against atherosclerosis compared to 
ApoA1 [94]. The Ac-hE18A-NH2 ApoE mimetic has been shown to have a superior 
ability than the 4F ApoA1 mimetic to reduce atherosclerotic lesions in Apoe−/− mice 
[95]. The Ac-hE18A-NH2 mimetic has also demonstrated more effective anti-
inflammatory properties than the 4F mimetic [96]. Most studies that have been 
carried out with the use of ApoE peptide mimetics are only in the pre-clinical trial 
stage and have not yet been tested in clinical studies for therapeutic use [94].
The variability of the outcomes of the pre-clinical and clinical studies described 
above points towards the need for a deeper understanding of the functionality 
(RCT and fat exchange, for example) and the structure of the HDL particles before 
considering them as a potential therapeutic for CVD. For example, a very recent 
study shows that the type of lipids used in the rHDL formulation has a significant 
effect on their ability to mediate cholesterol efflux [97], with saturated lipids 
having the greatest potential for cholesterol efflux. This mimics the results for fat 
exchange on simplistic models presented in Figure 3 and discussed in Section 4.1 in 
which saturated fats are more easily taken up by lipoproteins than unsaturated ones 
or those in the presence of cholesterol. Thus, not only the type of apolipoprotein 
but also the type of lipids used in the formulation have a fundamental role in the 
functionality of the rHDL and need to be further explored.
6. Conclusions
In this chapter we discussed the composition, function and structure of the 
two most studied lipoprotein types: LDL and HDL. In particular, we presented 
an updated model for determining the ultrastructure of LDL based on SAXS data 
that potentially enables determination of LDL phenotype from the total fraction 
measurement while highlighting structural differences in the small dense LDL 
subfraction between individuals with normal and high plasma serum triglyceride 
levels. Such differences, unknown until recently, may explain the different athero-
genic potential of small dense LDL subfractions between different individuals and 
help unravel the controversies related to their atherogenic potential. Moreover, the 
capacity of lipoprotein fractions and subfractions to transfer lipids and cholesterol 
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might be linked to these structural differences. Therefore, techniques that enable 
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manner are needed. We present recent data by fluorescence spectroscopy and 
neutron scattering showing how model cellular membranes lacking receptors can 
be used in the quantification of lipid exchange and lipid transfer by lipoproteins. 
In particular, the methodology might be especially useful when designing HDL 
therapy nanoparticles which require efficient removal of both saturated lipids and 
cholesterol from atherosclerotic plaque. Even though HDL therapy is quite promis-
ing in pre-clinics, it still has to show its potential in clinical studies.
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